D.E. Shaw & Co
AMRI

D.E. Shaw & Co’s Albany Molecular Research Inc AMRI Stock Holding History

D.E. Shaw & Co’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-318,662
Closed -$6.92M – 3737
2017
Q2 		$6.92M Buy
+318,662
New +$5.78M 0.01% 1124
2017
Q1 		– Sell
-71,747
Closed -$1.35M – 3767
2016
Q4 		$1.35M Buy
71,747
+34,483
+93% +$586K ﹤0.01% 2278
2016
Q3 		$615K Buy
37,264
+16,305
+78% +$242K ﹤0.01% 2675
2016
Q2 		$282K Sell
20,959
-59,659
-74% -$870K ﹤0.01% 3049
2016
Q1 		$1.23M Buy
80,618
+33,854
+72% +$531K ﹤0.01% 2219
2015
Q4 		$928K Buy
+46,764
New +$889K ﹤0.01% 2691
2015
Q3 		– Sell
-33,831
Closed -$684K – 4045
2015
Q2 		$684K Buy
33,831
+8,564
+34% +$165K ﹤0.01% 2968
2015
Q1 		$445K Buy
25,267
+1,690
+7% +$28.8K ﹤0.01% 3118
2014
Q4 		$384K Buy
+23,577
New +$433K ﹤0.01% 3504
2014
Q3 		– Sell
-28,755
Closed -$589K – 4576
2014
Q2 		$579K Buy
+28,755
New +$487K ﹤0.01% 3407
2013
Q3 		– Sell
-51,370
Closed -$610K – 4565
2013
Q2 		$610K Buy
+51,370
New +$556K ﹤0.01% 3103

Other funds holding AMRI

AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

D.E. Shaw & Co's AMRI Position: Q3 2017 in Review

D.E. Shaw & Co sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 318,662 shares — an estimated $6.92M sold.

D.E. Shaw & Co first reported a position in AMRI in Q2 2013 and held it in 11 quarters. The position peaked at $6.92M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

  • D.E. Shaw & Co reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
  • D.E. Shaw & Co sold 318,662 Albany Molecular Research Inc shares in Q3 2017, an estimated $6.92M.
  • D.E. Shaw & Co first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 11 quarters.
  • D.E. Shaw & Co's Albany Molecular Research Inc position peaked at $6.92M in Q2 2017.
  • 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on D.E. Shaw & Co's 13F filing for Q3 2017, filed 14 Nov 2017.